Over-the-counter sales of antibiotics for human use in India: The challenges and opportunities for regulation

Q2 Social Sciences
G. Porter, A. Kotwani, L. Bhullar, Jyoti Joshi
{"title":"Over-the-counter sales of antibiotics for human use in India: The challenges and opportunities for regulation","authors":"G. Porter, A. Kotwani, L. Bhullar, Jyoti Joshi","doi":"10.1177/09685332211020786","DOIUrl":null,"url":null,"abstract":"This article assesses the regulatory framework relating to over-the-counter (OTC) sales of antibiotics for human use in India. The OTC sale of antibiotics is recognised as a pathway for the emergence of antimicrobial resistance (AMR); a serious public health challenge in need of urgent regulatory responses. Analytically, this article identifies opportunities within existing laws in India and highlights gaps that need to be filled by modifying existing laws or developing new ones. Conceptually, it suggests a need to reflect on the limits of traditional, top-down, ‘command-and control’ regulation and to think about alternative approaches. The article therefore advocates for an approach to regulation that incorporates two elements. First, it argues for a broader concept of regulation that encompasses binding as well as non-binding regulatory instruments and initiatives aimed at influencing stakeholder behaviour (including soft regulation, economic incentives, information campaigns and uses of technology). Second, it makes the case for enhanced stakeholder participation in regulatory design. The article will be relevant for health policy and drug regulators in India and other low- and middle-income countries, as well as legal scholars, social scientists and others interested in the regulation of OTC sales of antibiotics for AMR containment.","PeriodicalId":39602,"journal":{"name":"Medical Law International","volume":"21 1","pages":"147 - 173"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/09685332211020786","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Law International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09685332211020786","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Social Sciences","Score":null,"Total":0}
引用次数: 16

Abstract

This article assesses the regulatory framework relating to over-the-counter (OTC) sales of antibiotics for human use in India. The OTC sale of antibiotics is recognised as a pathway for the emergence of antimicrobial resistance (AMR); a serious public health challenge in need of urgent regulatory responses. Analytically, this article identifies opportunities within existing laws in India and highlights gaps that need to be filled by modifying existing laws or developing new ones. Conceptually, it suggests a need to reflect on the limits of traditional, top-down, ‘command-and control’ regulation and to think about alternative approaches. The article therefore advocates for an approach to regulation that incorporates two elements. First, it argues for a broader concept of regulation that encompasses binding as well as non-binding regulatory instruments and initiatives aimed at influencing stakeholder behaviour (including soft regulation, economic incentives, information campaigns and uses of technology). Second, it makes the case for enhanced stakeholder participation in regulatory design. The article will be relevant for health policy and drug regulators in India and other low- and middle-income countries, as well as legal scholars, social scientists and others interested in the regulation of OTC sales of antibiotics for AMR containment.
印度人用抗生素的非处方销售:监管的挑战和机遇
本文评估了与印度人用抗生素的非处方(OTC)销售有关的监管框架。抗生素的非处方销售被认为是产生抗菌素耐药性(AMR)的途径;需要紧急监管对策的严重公共卫生挑战。通过分析,本文确定了印度现有法律中的机会,并强调了需要通过修改现有法律或制定新法律来填补的空白。从概念上讲,它表明有必要反思传统的、自上而下的、“命令和控制”式监管的局限性,并考虑替代方法。因此,本文提倡一种包含两个要素的监管方法。首先,它主张一个更广泛的监管概念,包括约束性和非约束性监管工具以及旨在影响利益相关者行为的举措(包括软监管、经济激励、信息宣传和技术使用)。其次,它提出了加强利益相关者参与监管设计的理由。这篇文章将与印度和其他低收入和中等收入国家的卫生政策和药品监管机构,以及法律学者、社会科学家和其他对管制用于遏制抗生素耐药性的抗生素的非处方销售感兴趣的人有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Law International
Medical Law International Social Sciences-Law
CiteScore
2.60
自引率
0.00%
发文量
14
期刊介绍: The scope includes: Clinical Negligence. Health Matters Affecting Civil Liberties. Forensic Medicine. Determination of Death. Organ and Tissue Transplantation. End of Life Decisions. Legal and Ethical Issues in Medical Treatment. Confidentiality. Access to Medical Records. Medical Complaints Procedures. Professional Discipline. Employment Law and Legal Issues within NHS. Resource Allocation in Health Care. Mental Health Law. Misuse of Drugs. Legal and Ethical Issues concerning Human Reproduction. Therapeutic Products. Medical Research. Cloning. Gene Therapy. Genetic Testing and Screening. And Related Topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信